5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond

Keyphrases

• 5ARI 75%
• 5α-reductase Inhibitors 100%
• Adverse Events Profile 25%
• Aging Men 25%
• Benign Prostatic Hyperplasia 25%
• Cancer Cases 25%
• Chemoprevention 100%
• Detection Rate 25%
• Dutasteride 25%
• Finasteride 75%
• Further Analysis 50%
• Gleason Score 7 25%
• High-risk Population 25%
• Non-associated 25%
• Population Modeling 25%
• Prostate Cancer 100%
• Prostate Cancer Chemoprevention 25%
• Prostate Cancer Prevention Trial 100%
• Prostate Volume 25%
• Prostate-specific Antigen Level 25%
• Prostatitis 25%
• Public Health Risk 25%
• Random Data 25%
• Reduced Likelihood 25%
• Risk Perspectives 25%
• Risk-benefit 25%
• Substantial Reduction 25%
• Tolerability 25%
• Tumor 25%

Medicine and Dentistry

• Adverse Event 11%
• Cancer Prevention 100%
• Chemoprevention 11%
• Chemoprophylaxis 100%
• Disease 11%
• Dutasteride 11%
• High Risk Population 11%
• Neoplasm 11%
• Oxidoreductase 100%
• Pilus 33%
• Prostate Cancer 100%
• Prostate Hypertrophy 11%
• Prostate Specific Antigen 11%
• Prostatitis 11%
• Public Health 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 11%
• Disease 11%
• Dutasteride 11%
• Finasteride 33%
• Neoplasm 11%
• Oxidoreductase 100%
• Prostate Cancer 100%
• Prostate Hypertrophy 11%
• Prostate Specific Antigen 11%
• Prostatitis 11%
• Tolerability 11%